Clinical Trial Detail

NCT ID NCT01968109
Title Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

hepatocellular carcinoma

urinary bladder cancer

head and neck cancer

colorectal cancer

melanoma

non-small cell lung carcinoma

ovarian cancer

cervical cancer

stomach cancer

Therapies

Nivolumab + Relatlimab

Relatlimab

Age Groups: adult

No variant requirements are available.